Minerva Neurosciences | NERV - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Adma Biologics USD 88.82M 13.19M 2025-12
ALKERMES USD 331.33M 7M 2026-03
AstraZeneca USD 12.61B 225M 2026-03
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Cipla INR 39.1B 2.54B 2026-03
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 63.8M 63.56M 2025-12
CSL USD 4.46B 2.71B 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
GlaxoSmithKline GBP 5.75B 429M 2026-03
Grifols EUR 766.49M 39.74M 2024-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
J&J USD 17.24B 642M 2026-03
Merck USD 10.85B 2.57B 2025-12
Minerva Neurosciences -4.27M 26.79M 2024-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Novartis USD 10.07B 184M 2026-03
Novavax USD 125.04M 76.09M 2025-12
Pfizer USD 11.04B 1.24B 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Takeda JPY 688.84B 101.71B 2026-03
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12